LFMD Insider Filing: 25,000 Performance Shares Vested for CTO

Rhea-AI Filing Summary

LifeMD, Inc. (LFMD) reporting person Dennis Wijnker, identified as an officer with the title Chief Technology Officer, reported a change in beneficial ownership on 08/22/2025. The Form 4 shows a grant of 25,000 shares of common stock that vested on that date with an acquisition price recorded as $0, described as performance stock. After the vesting, the reporting person beneficially owned 175,000 shares. The form is signed and dated 08/26/2025. The filing indicates this was a routine vesting event rather than an open-market purchase or sale.

Positive

• Transparent disclosure of executive equity vesting in a timely Form 4 filing
• Modest ownership stake retained by the officer after vesting (175,000 shares), aligning management with shareholders

Negative

• No details provided on the performance conditions or original grant date, limiting assessment of the grant's performance basis
• Acquisition price listed as $0 with no fair-value context disclosed in this form, preventing evaluation of compensation expense or dilution

Insights

Financial Analyst

TL;DR: Routine insider vesting of performance shares; modest share increase with limited immediate market impact.

The report documents a grant of 25,000 common shares that vested for the Chief Technology Officer on 08/22/2025 at a recorded price of $0, increasing his beneficial ownership to 175,000 shares. This is a compensation-related transaction rather than a purchase or sale. Because the change arises from vested performance stock, it does not reflect an incremental cash investment or disposition and is typically viewed as part of executive compensation plans. The filing contains no information about performance conditions, fair value, or subsequent disposition plans, so assessment of long-term dilution or expense impact cannot be made from this form alone.

Corporate Governance Expert

TL;DR: Compensation vesting disclosed as required; no regulatory or governance red flags in the filing.

The Form 4 discloses that 25,000 performance shares vested for an officer on 08/22/2025 and the reporting person now beneficially owns 175,000 shares. The transaction is marked as an acquisition via vesting (code A) with an acquisition price of $0, consistent with equity grants settling upon vesting. The form is properly signed. The filing does not indicate any concurrent sales, 10b5-1 plan usage, or amendments that would raise governance concerns. Additional context on grant terms or company-wide dilution would require other filings or proxy disclosures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wijnker Dennis

(Last) (First) (Middle)

536 FIFTH AVENUE

SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		A		25,000	A	$0(1)	175,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of performance stock which vested on August 22, 2025

	/s/ Dennis Wijnker	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change did Dennis Wijnker report for LifeMD (LFMD)?

He reported the vesting of 25,000 common shares on 08/22/2025, increasing his beneficial ownership to 175,000 shares.

Was the transaction a purchase or sale on the open market?

No. The Form 4 records an acquisition via vesting (performance stock) at a recorded price of $0, not an open-market trade.

What is Dennis Wijnker's role at LifeMD according to the filing?

He is listed as an officer with the title Chief Technology Officer on the Form 4.

When was the Form 4 signed and filed?

The signature block shows the form signed by /s/ Dennis Wijnker dated 08/26/2025.

Does the Form 4 provide details on the performance conditions for the granted shares?

No. The filing states the shares represent performance stock that vested but does not disclose the specific performance metrics or original grant date.